Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
DepressantNo dose data on record for this route. The timings below are not a dose guide.
morphine, fentanyl, heroin +3 moremorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone show less
Carfentanil
Carfentanil is a synthetic opioid of the anilidopiperidine class. It is approximately 100 times more potent than fentanyl,[1][2] occupying the extreme end of the opioid potency spectrum. Carfentanil is a full agonist at µ-opioid receptors,[3] producing its effects by suppressing pain signaling and depressing respiratory drive.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
DepressantNo dose data on record for this route. The timings below are not a dose guide.
morphine, fentanyl, heroin +3 moremorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone show less
Synthesized in 1974, carfentanil was developed for veterinary immobilization of large wildlife and marketed as Wildnil.[3] In 2002, Russian security forces aerosolized it during a Moscow theater hostage siege, killing approximately 130 people. Since 2016, it has appeared as an invisible adulterant in the illicit opioid supply, causing mass overdose deaths;[2] no approved human use exists in any jurisdiction.
Subjective effects include intense euphoria, pain suppression, heavy sedation, and a dissolving of anxiety. These effects are inferred entirely from opioid pharmacology — no controlled human data exist, and the onset-to-loss of consciousness window may be measured in seconds. Characteristic unsought effects include chest wall rigidity that mechanically blocks breathing, a slowing heartbeat, and rapid loss of consciousness.
Dependence liability is high, and the estimated lethal dose of roughly 20 µg[3] leaves no margin between an active and a fatal dose. Standard naloxone often fails — carfentanil binds opioid receptors in ways that resist displacement,[4] its effects outlast naloxone by hours,[5] and blood concentrations in survivors and fatalities overlap.[6][7] No controlled human studies have been published; the evidence base rests on veterinary pharmacology, forensic toxicology, and laboratory receptor data.
History[edit]
Discovery
Carfentanil was synthesized on May 2, 1974, at Janssen Pharmaceutica by a team led by Paul Janssen.[3] It emerged from the same structural series that had produced fentanyl in 1960,[8] with a U.S. patent granted in 1979.[3]
Veterinary use and the Moscow theater crisis
In 1986, carfentanil entered veterinary practice as Wildnil for remote dart immobilization of elephants, rhinoceroses, and other large wildlife;[3] commercial production ceased in 2003 due to diversion risk.[9] In October 2002, Russian security forces aerosolized carfentanil and remifentanil into Moscow's Dubrovka Theater during a hostage siege; approximately 130 of 850 hostages died, primarily from respiratory failure compounded by insufficient naloxone and improper positioning of unconscious victims.[10][11]
Illicit supply and international scheduling
Carfentanil entered the North American illicit drug supply in 2016 as an adulterant in heroin and counterfeit opioid tablets, with overdose deaths documented across ten US states;[2] standard laboratory screening missed it in 104 of 134 carfentanil-positive postmortem cases in Miami-Dade County alone.[12] China regulated it in March 2017,[3] and in December 2017 the WHO recommended the most stringent level of international control.[13]
The name carfentanil is a contraction of its systematic designation as 4-carbomethoxyfentanyl. In veterinary and law enforcement contexts, the Wildnil brand name persisted as a reference point long after production ceased. A single kilogram seizure at Vancouver airport in June 2016 represented millions of potential lethal doses[3]}; for drug policy analysts and first responders, the compound became shorthand for the escalating potency of the synthetic opioid supply.
Chemistry[edit]
Structural class
Carfentanil belongs to the 4-anilidopiperidine chemical class, sharing its core scaffold with fentanyl, sufentanil, alfentanil, and remifentanil.[14] What distinguishes it from fentanyl is a methyl ester group added at one position of the piperidine ring, which dramatically increases its opioid receptor affinity.[14] Its molecular formula is C₂₄H₃₀N₂O₃ (molecular weight 394.5 g/mol).
Physical properties
Carfentanil has no stereocenters — it is an achiral molecule with no active or inactive isomers.[14] The compound is highly lipophilic, meaning it crosses biological membranes rapidly and can be absorbed through intact skin, mucous membranes, and the lungs.[3] This was confirmed operationally when it was aerosolized as an incapacitating agent in 2002.[10]
Pharmacology[edit]
Mechanism of action
Carfentanil is a full opioid agonist — it activates the same receptors as morphine and fentanyl, but at far lower concentrations.[15] Receptor activation suppresses pain, produces sedation and euphoria, and depresses the drive to breathe in a dose-dependent way.
It locks opioid receptors into conformations that are 10–100 times harder for naloxone to displace than those produced by other opioids,[4] and it unbinds from those receptors far more slowly than other fentanyl analogs.[5] These two features make reversal markedly more difficult than for any other opioid in the illicit supply.
Pharmacokinetics
No controlled human pharmacokinetic studies exist. The estimated serum half-life is approximately 5.7 hours — longer than fentanyl's 3.7 hours[15] — and one metabolite retains potency comparable to the parent compound,[15][16] meaning effects can outlast what the half-life alone predicts. Naloxone's half-life is roughly 33 minutes, creating a high risk of renarcotization after apparent reversal.[17]
Neuroscience[edit]
Where it acts
Carfentanil activates opioid receptors concentrated in the brain's reward circuitry, pain-modulation centers, and the brainstem nuclei that control breathing.[18] In the mesolimbic pathway, this produces intense euphoria. In the brainstem, it slows the breathing rate and reduces the brain's sensitivity to rising carbon dioxide.[17]
Why it matters
As a radiolabeled PET tracer, [¹¹C]carfentanil is the most widely used tool for imaging opioid receptors in the living human brain.[19] Hundreds of studies using this tracer have mapped opioid receptor activity during pain, stress, social rejection, and addiction — at doses far below any pharmacological threshold.
Key unresolved questions include whether carfentanil's β-arrestin signaling[20] contributes to the speed and severity of respiratory arrest, and how much overdose lethality comes from the active metabolite versus the parent compound.[16] Evidence also suggests cardiovascular collapse in carfentanil overdose may involve brain signaling pathways distinct from classical opioid respiratory depression[21] — a distinction with implications for optimal rescue pharmacology.
Subjective Effects[edit]
Carfentanil has no characterizable subjective experience. The compound moves from first effect to loss of consciousness in seconds — a window so narrow that every documented human exposure is an unintentional overdose. What opioid pharmacology predicts as euphoria and sedation arrives already indistinguishable from overdose.
Compared to fentanyl — itself at the extreme end of clinically encountered opioid potency — carfentanil is approximately 50–100 times more potent for respiratory depression[5] and binds opioid receptors in a way far more resistant to naloxone reversal.[4] No other opioid in the illicit supply approaches this combination.
Synthesized in 1974 at Janssen Pharmaceutica under Paul Janssen,[4] carfentanil was developed exclusively for veterinary immobilization of large wildlife and marketed as Wildnil. In 2016 it appeared as an adulterant in the North American heroin supply, triggering a wave of overdose deaths across multiple states.[2] No approved human therapeutic use exists; it is subject to the most stringent international drug control measures.
Subjective effects include intense euphoria, profound sedation, analgesia, and anxiolysis — inferred entirely from µ-opioid receptor class pharmacology, as no controlled human data exist. The transition from onset to life-threatening toxicity occurs within seconds to minutes, leaving no meaningful experiential window distinct from overdose. Chest wall rigidity, bradycardia, and rapid loss of consciousness are characteristic unsought effects.
The estimated lethal dose — approximately 20 µg — leaves no margin between any active dose and a fatal one,[4] and abuse liability is high by class inference. Slow receptor dissociation[5] and naloxone-resistant receptor conformations[6] make standard overdose reversal potentially inadequate; fatal and non-fatal blood concentrations overlap.[7][8] No controlled human studies have been published; the evidence base rests on veterinary pharmacology, forensic toxicology, and in vitro receptor data.
History[edit]
Discovery
Carfentanil — originally designated 4-carbomethoxyfentanyl — was synthesized on May 2, 1974, at Janssen Pharmaceutica in Beerse, Belgium, by the medicinal chemistry team led by Paul Janssen.[4] It emerged from the same systematic exploration of anilidopiperidine analogs that had produced fentanyl in 1960. The first published description appeared in a 1976 structure-activity relationship study by Van Daele and colleagues, which identified carfentanil as among the most potent compounds in the series.[9] A U.S. patent was granted in 1979.[4]
Veterinary use and the Moscow theater crisis
In 1986, carfentanil entered veterinary practice under the brand name Wildnil for remote dart immobilization of elephants, rhinoceroses, and other large wildlife.[4] Commercial production ceased in 2003 due to diversion risk.[10]
In October 2002, Russian security forces aerosolized a chemical agent containing carfentanil and remifentanil into Moscow's Dubrovka Theater during a hostage siege.[4] Approximately 130 of 850 hostages died, primarily from respiratory failure compounded by insufficient naloxone and improper positioning of unconscious victims.[11][12] The event remains the only confirmed large-scale deployment of carfentanil as an incapacitating chemical agent.
Illicit supply and international scheduling
Carfentanil entered the North American illicit drug supply in 2016 as an adulterant in heroin and counterfeit opioid tablets. The CDC documented its presence in overdose deaths across ten US states during July–December of that year.[2] In Miami-Dade County alone, 104 of 134 carfentanil-positive postmortem cases were initially missed by standard laboratory screening.[13]
China — identified as the primary illicit manufacturing source — regulated carfentanil in March 2017.[4] In December 2017, the WHO recommended placement in both Schedule I and Schedule IV of the 1961 Single Convention — the most stringent level of international control.[14]
The name carfentanil derives from its systematic designation as 4-carbomethoxyfentanyl — a contraction reflecting its structural parentage. In veterinary and law enforcement contexts, the Wildnil brand name persisted as a reference point long after production ceased. Among drug policy analysts and first responders, carfentanil became shorthand for the escalation of synthetic opioid potency in the illicit supply — a single kilogram seizure at Vancouver airport in June 2016 represented millions of potential lethal doses.[4]
Chemistry[edit]
Structural class
Carfentanil belongs to the 4-anilidopiperidine chemical class, sharing the parent scaffold with fentanyl, sufentanil, alfentanil, and remifentanil.[15] The defining structural feature is a piperidine ring bearing an anilide substituent at the 4-position. What distinguishes carfentanil from fentanyl is a methyl ester group (carbomethoxy) at C4 of the piperidine ring, which dramatically increases µ-opioid receptor affinity.
Molecular properties
| Molecular formula | C₂₄H₃₀N₂O₃ |
| Molecular weight | 394.5 g/mol |
The molecule consists of a piperidine ring nitrogen alkylated with a 2-phenylethyl chain, a propanoyl-N-phenylamide at C4, and a methyl ester at C4.[15] The C4 carbon is quaternary, bearing both the anilidopropanoyl group and the ester.
Stereochemistry
Carfentanil has no stereocenters — the quaternary C4 carbon carries symmetric substituents relative to the ring, producing an achiral molecule. No active or inactive isomers have been described.[15]
Physical properties
The compound is sufficiently lipophilic to cross biological membranes rapidly, enabling absorption through skin, mucous membranes, and the lungs.[4] This property was demonstrated operationally in its confirmed use as an aerosolized incapacitating agent in 2002.[11] Pharmacologically active quantities are in the nanogram-to-microgram range — far below the threshold of visual detection.
Pharmacology[edit]
Mechanism of action
Carfentanil is a full agonist at the µ-opioid receptor, activating the same signaling cascade as morphine and fentanyl but at far lower concentrations — functional potency is sub-nanomolar.[3] Receptor activation suppresses pain signaling, produces sedation and euphoria, and depresses respiratory drive in a dose-dependent manner.
At equivalent levels of receptor occupancy, carfentanil is approximately eight times more efficient than morphine or fentanyl at inhibiting downstream signaling, indicating that it locks the receptor into uniquely active conformations.[6] These conformations are resistant to displacement by naloxone — the standard overdose reversal agent — showing 10–100-fold reduced sensitivity compared to other opioids.[6]
A defining pharmacological feature is slow receptor dissociation: carfentanil unbinds from the µ-opioid receptor substantially more slowly than other fentanyl analogs.[5] This contributes to prolonged pharmacological action and the difficulty of competitive antagonist reversal. The compound is highly selective for the µ-opioid receptor, a property that has made it the gold-standard PET radiotracer for imaging this receptor in the living human brain.[16]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. All parameters derive from in vitro incubation or animal modeling.
The estimated human serum half-life is approximately 5.7 hours — notably longer than fentanyl's half-life of approximately 3.7 hours.[3] This has direct implications for overdose management: carfentanil's effects substantially outlast naloxone's elimination half-life of approximately 33 minutes, creating significant renarcotization risk.[17]
The primary metabolite (norcarfentanil) has minimal opioid activity. A second metabolite retains comparable potency to the parent compound,[3][18] potentially prolonging pharmacological effects beyond what the parent half-life predicts. Phase II metabolism involves glucuronide and sulfate conjugation.[19]
Documented routes of human exposure include intravenous injection, intranasal insufflation, oral ingestion, transdermal absorption through intact skin, mucous membrane absorption, and inhalation.[4] In research settings, [¹¹C]carfentanil is administered intravenously at nanogram-per-kilogram tracer doses for PET imaging.[20]
Neuroscience[edit]
Where it acts
Carfentanil activates µ-opioid receptors concentrated in the brain's reward circuitry (ventral tegmental area, nucleus accumbens), pain-modulation centers (periaqueductal gray, rostral ventromedial medulla), and respiratory control nuclei (pre-Bötzinger complex).[20] In the mesolimbic pathway, activation disinhibits dopamine neurons, producing intense euphoria. In pain centers, it suppresses transmission of pain signals to the spinal cord. In brainstem respiratory nuclei, it depresses breathing rate and reduces the brain's sensitivity to carbon dioxide buildup.[17]
Why it matters
As [¹¹C]carfentanil, the compound serves as the most widely used PET radiotracer for mapping µ-opioid receptors in the living human brain.[16] Hundreds of published PET studies using this tracer have generated one of the most complete maps of any neurotransmitter system in neuroscience, enabling measurement of endogenous opioid release during pain, stress, social rejection, and addiction. The scientific contribution is the map — the radiotracer doses used are far below any pharmacological threshold.
Key unresolved questions include whether carfentanil's preferential recruitment of β-arrestin[21] directly contributes to the speed and severity of respiratory arrest, and what proportion of overdose lethality is attributable to the active metabolite versus the parent compound.[18] Preliminary evidence suggests cardiovascular collapse in carfentanil overdose may involve noradrenergic mechanisms distinct from classical opioid respiratory depression,[22] a distinction with implications for optimal rescue pharmacology.
Subjective Effects[edit]
No controlled human experiential data exist for carfentanil. Its extreme potency — with an estimated lethal dose of approximately 20 µg — means essentially all documented human exposures are unintentional overdoses rather than deliberate use. The effect profile is inferred entirely from µ-opioid receptor class pharmacology: intense euphoria, analgesia, sedation, and anxiolysis compressed into an exposure window so narrow that the boundary between onset and life-threatening toxicity may be measured in seconds. Route of administration is a critical variable — intravenous and inhaled routes produce near-instantaneous onset, while transdermal contact introduces unpredictable delay.
Compared to fentanyl — itself at the extreme end of clinically encountered opioid potency — carfentanil is approximately 50–100 times more potent for respiratory depression and exhibits far slower receptor dissociation,[5] making antagonist reversal markedly more difficult. No other opioid in the illicit supply combines this level of potency with this degree of resistance to naloxone.[6]
Effect Grid
No common dose exists for carfentanil in any context of human use. The compound was developed exclusively for veterinary immobilization of large wildlife (elephants, rhinoceroses) and has no approved human therapeutic indication. Essentially all documented human exposures are unintentional overdoses from adulterated heroin or counterfeit pills.
The concept of a common dose implies a range where most users experience characteristic effects with manageable risk. For carfentanil, no such range can be identified: the estimated lethal dose (~20 µg) is indistinguishable from any potentially experiential dose.
Forensic case series show substantial overlap between blood concentrations in surviving impaired individuals and fatal cases, confirming the absence of any predictable dose-response relationship.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Visual processing suppression
Pain suppression · Physical fatigue · Bodily heaviness · Body high · Constipation · Muscle relaxation · Nausea · Spontaneous body sensations · Tactile euphoria · Abnormal heartbeat · Dizziness · Dry mouth · Excessive sweating · Sexual arousal suppression · Temperature dysregulation · Tingling / electric sensations · Vomiting · Muscle tension · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Body high · Constipation · Muscle relaxation · Nausea · Spontaneous body sensations · Tactile euphoria · Dizziness · Dry mouth · Excessive sweating · Sexual arousal suppression · Temperature dysregulation · Tingling / electric sensations · Vomiting · Muscle tension · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Focus suppression · Information processing suppression · Thought deceleration · Cognitive euphoria · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Amnesia
Cognitive euphoria · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization
Anxiety
Depersonalization · Derealization · Cognitive disconnection
Timeline
Slightly delayed onset compared to IV due to mucosal absorption. Effects emerge within 1–5 minutes. Rapid progression to loss of consciousness and respiratory depression expected at any pharmacologically active dose.
Maximal opioid effects if survived. Complete sedation, respiratory depression, bradycardia, and miosis. Duration estimated from fentanyl intranasal class data with extension for carfentanil's slower receptor dissociation.
Gradual decline complicated by active metabolite M2/M0 and slow µOR dissociation. Renarcotization risk persists as naloxone wears off far sooner than carfentanil's pharmacological effects resolve.
Residual sedation and cognitive impairment. Active metabolite continues to contribute opioid effects.
⚠ Do not drive or operate machinery for at least 24 hours after any carfentanil exposure; extended medical monitoring is required due to renarcotization risk.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Critical
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · heroin
Toxicity
Estimated lethal dose
The estimated human lethal dose is approximately 20 µg — equivalent to a few grains of table salt.[3] safety citation needed There is no meaningful therapeutic index for human use. The margin between any pharmacologically active dose and a lethal dose is effectively zero.
Postmortem and forensic data
Blood concentrations in carfentanil-only deaths range from <0.2 to 0.73 ng/mL,[6] while surviving impaired individuals show concentrations of <0.04–2.1 ng/mL[7] — ranges that overlap. No blood concentration reliably distinguishes survival from death. In polydrug deaths, concentrations reach up to 9.2 ng/mL.[22]
Heart and circulation
A slowed heart rate occurs consistently alongside respiratory depression in animal models,[23] including at PET tracer doses.[24] Cardiac arrest is a common cause of death in overdose.[5]
Chest wall rigidity
High doses can lock the chest wall and diaphragm muscles, mechanically preventing breathing independent of the brain's respiratory depression.[25] This compounds the central respiratory effect and accelerates fatal outcomes.
Detection challenges
Carfentanil is not detectable by standard drug screening — immunoassay panels and standard GC-MS miss it entirely; 104 of 134 carfentanil-positive cases in Miami-Dade County were initially missed by conventional screening.[12] Fentanyl test strips do not reliably detect it.[26] LC-MS/MS is required for reliable detection.[22][6]
Exposure routes
Toxicity occurs via injection, insufflation, ingestion, transdermal absorption through intact skin, mucous membrane absorption, and inhalation.[3] Occupational exposure is documented for veterinarians, law enforcement, first responders, and forensic laboratory workers.[3]
Psychological Risks
No controlled data on carfentanil-specific psychological effects exist. By class inference, acute risks include rapid progression from cognitive euphoria to confusion and loss of consciousness, delirium during partial recovery or incomplete reversal, amnesia for the exposure period, and acute anxiety and dysphoria if naloxone precipitates withdrawal. inferred
The compound's potency means the window between onset of subjective effects and unconsciousness is likely seconds to minutes for most routes. inferred
Tolerance & Dependence
No human studies on tolerance or dependence exist; all assessments are class-level inferences from opioid pharmacology. Tolerance develops via receptor desensitization, and carfentanil's signaling pattern[20] is associated with faster development than typical opioids.
Physical dependence follows the standard opioid withdrawal pattern — Anxiety, Dysphoria, muscle pain, sweating, runny nose, insomnia, and gastrointestinal distress. Severity has not been characterized but would be expected to be severe given the compound's extreme potency and long half-life. Dependence liability is high by class inference, and cross-tolerance is expected with all opioid agonists. inferred
Drug Interactions
The dominant risk is CNS depressant synergy: combining carfentanil with benzodiazepines, alcohol, other opioids, or gabapentinoids produces synergistic respiratory depression. Most carfentanil overdose deaths involve polydrug toxicity,[22] and because carfentanil enters the supply as an adulterant, co-exposure with other depressants is the norm.
Standard naloxone shows 10–100-fold reduced potency against carfentanil.[4] Nalmefene has superior reversal characteristics due to higher receptor affinity and a longer half-life,[27][28] and naltrexone is approximately 65 times more potent than naloxone at displacing carfentanil from opioid receptors.[4] CYP3A4/3A5 inhibitors — azole antifungals, macrolide antibiotics, HIV protease inhibitors, and grapefruit juice — are expected to increase carfentanil concentrations and toxicity.[29] safety citation needed
Contraindications
7 knownNo substance-specific contraindication studies exist. The following are class-level inferences.
Absolute contraindications:
- Concurrent CNS depressant use — synergistic respiratory depression is the leading cause of carfentanil-associated death[22]
- Respiratory compromise — COPD, sleep apnea, and similar conditions lower the lethal threshold
- Absence of reversal agents — any exposure context without immediately available naloxone or nalmefene
Relative contraindications:
- CYP3A4/3A5 inhibitor co-administration — expected increase in blood concentrations[29]
- Liver impairment — reduced clearance may prolong and intensify effects
- Heart conditions — slowed heart rate is a documented effect[23] and may worsen pre-existing cardiac conduction problems
- Pregnancy — opioids cross the placenta; carfentanil's extreme potency amplifies fetal risk inferred
safety citation needed All contraindications are class-level inferences.
Harm Reduction[edit]
Forms & Identification
Carfentanil is never sold as a standalone product. It enters the drug supply as an invisible adulterant in heroin, counterfeit prescription pills, and powder sold as fentanyl. The compound is active at quantities far below visual detection — distinguishing a contaminated sample by appearance is impossible.
Standard fentanyl test strips do not reliably detect carfentanil,[26] and standard immunoassay drug panels miss it entirely.[12] Only LC-MS/MS provides definitive identification. A negative fentanyl strip result does not rule out carfentanil contamination.
Guidelines
- Never use alone. Carfentanil can cause unconsciousness and respiratory arrest within seconds. A witness who can call for help and administer naloxone is critical.
- Carry naloxone — and carry extra. Standard naloxone doses may be insufficient for carfentanil. Multiple doses should be immediately accessible.
- Start with a test dose. When using any unregulated opioid, use a small amount first and wait. This does not eliminate risk from carfentanil contamination — the compound is active at invisible quantities — but may reduce the probability of a full lethal exposure.
- Avoid mixing with other depressants. Benzodiazepines, alcohol, and other opioids dramatically increase the risk of fatal respiratory depression.
- Use supervised consumption sites where available. Trained staff with naloxone and emergency equipment provide the highest level of protection against overdose death.
Set & Setting
Carfentanil exposure is almost exclusively unintentional. There is no safe set or setting for deliberate use — the margin between an active and lethal dose is effectively zero. For people who use unregulated opioids, the single most important environmental factor is never using alone. A second person who can recognize overdose and administer naloxone is the only practical safeguard against a rapid fatal outcome.
Aftercare & integration. Carfentanil exposure is rarely deliberate, and aftercare is primarily medical. Anyone who survives a carfentanil-related overdose should remain under medical observation for several hours — the compound's long half-life and active metabolite create a sustained risk of renarcotization after initial naloxone reversal.
Physical recovery after opioid overdose may involve persistent fatigue, nausea, muscle soreness, and cognitive fog for 24–72 hours. Precipitated withdrawal from naloxone administration can produce intense anxiety, agitation, and pain. These symptoms are temporary but distressing, and medical support should be sought if they persist.
Overdose is a traumatic event for survivors and witnesses. Peer support organizations, crisis counseling, and harm reduction services can help with emotional recovery and safety planning to reduce future risk.
Recovery & Support
Opioid dependence — whether involving carfentanil, fentanyl, or heroin — is a treatable condition. Evidence-based options include:
- Opioid agonist therapy (methadone, buprenorphine) — reduces cravings, prevents withdrawal, and lowers overdose risk. This is the most effective treatment for opioid use disorder and can be maintained long-term.
- Naltrexone (extended-release injection) — blocks opioid effects and reduces relapse risk. Requires full detoxification before initiation.
- Peer support — organizations such as SMART Recovery and Narcotics Anonymous provide community-based support.
- Harm reduction services — syringe service programs, naloxone distribution, and supervised consumption sites reduce immediate risks while supporting pathways to treatment.
Recovery is not linear. Relapse is common and does not represent failure — it represents an ongoing condition requiring adjusted support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
- Slow, shallow, or stopped breathing
- Blue or gray lips and fingertips
- Gurgling or snoring sounds from an unconscious person
- Unresponsive to stimulation (sternal rub, loud voice)
- Chest wall rigidity — the chest feels stiff and does not rise with breaths
Immediate steps
- 1. Call emergency services immediately. Do not wait to see if the person recovers.
- 2. Administer naloxone (intranasal or intramuscular). Give a second dose after 2–3 minutes if there is no response. Carfentanil may require multiple naloxone doses — standard dosing is often insufficient.[4]
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Perform rescue breathing if the person is not breathing and training permits.
- 5. Stay with the person. Renarcotization is likely — carfentanil's effects outlast naloxone by hours.[17]
What to tell the dispatcher
State that the person is unresponsive with slowed or stopped breathing. Say "possible opioid overdose — may involve carfentanil or fentanyl structural analog." Provide the time symptoms were noticed and any substances known to have been used. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents
Naloxone is the standard opioid antagonist but may require repeated or higher-than-standard doses for carfentanil. Nalmefene, where available, has superior reversal characteristics due to higher receptor affinity and a longer half-life.[27][28] Even after apparent reversal, prolonged medical monitoring is essential — carfentanil's half-life of approximately 5.7 hours far exceeds naloxone's 33-minute half-life.
Legal Status[edit]
Carfentanil is subject to the most stringent international drug controls, with no approved human use anywhere in the world.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I and Schedule IV, 1961 Single Convention | Most stringent international control; WHO recommendation December 2017[13] |
| United States | Schedule II (Controlled Substances Act) | DEA ACSCN 9743; annual manufacturing quota 19 grams (2016); retains Schedule II due to historical veterinary use[9] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment and/or unlimited fine; supply: up to life imprisonment and/or unlimited fine[9] |
| Australia | Schedule 8 (Poisons Standard) | Added June 2017; controlled/restricted substance[9] |
| Canada | Controlled substance | Controlled under federal legislation[9] |
| European Union | Individually scheduled by member states | Formal risk assessment conducted by European drugs agency; widespread scheduling across member states |
| China | Controlled | Regulated March 2017 following identification as major illicit supply source[3] |
Legal status varies by jurisdiction and changes over time. This information is not legal advice.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Critical
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · heroin
Toxicity
Estimated lethal dose
The estimated human lethal dose is approximately 20 µg — equivalent to a few grains of table salt — extrapolated from analogy with etorphine, not experimentally determined.[4] safety citation needed There is no meaningful therapeutic index for human use. The margin between any pharmacologically active dose and a lethal dose is effectively zero.
Postmortem and forensic data
Postmortem blood concentrations in carfentanil-only deaths range from <0.2 to 0.73 ng/mL,[7] while surviving impaired individuals show concentrations of <0.04–2.1 ng/mL.[8] This overlap confirms that no blood concentration reliably distinguishes survival from death. In polydrug deaths, concentrations range up to 9.2 ng/mL.[23]
Heart and circulation
Slowed heart rate is a consistent finding alongside respiratory depression in animal models.[24] Dose-dependent heart rate decreases occur even at PET tracer doses in anesthetized rats.[25] Cardiac arrest is a common cause of death in overdose.[5]
Chest wall rigidity
Ultra-potent synthetic opioids including carfentanil can produce acute skeletal muscle rigidity affecting the chest wall and diaphragm — mechanically preventing breathing independent of central respiratory depression.[26] This effect compounds the central respiratory depression and accelerates fatal outcomes.
Detection challenges
Carfentanil is not detectable by standard drug screening — immunoassay panels and standard GC-MS miss it. In Miami-Dade County, 104 of 134 carfentanil-positive cases were initially missed by conventional screening.[13] LC-MS/MS is required for reliable detection.[23][7] Fentanyl test strips do not reliably detect carfentanil.[27]
Exposure routes
Toxicity occurs via injection, insufflation, ingestion, transdermal absorption through intact skin, mucous membrane absorption, and inhalation.[4] Occupational exposure is documented for veterinarians, law enforcement, first responders, and forensic laboratory workers.[4]
Psychological Risks
No controlled data on carfentanil-specific psychological effects exist. By class inference from µ-opioid agonism, acute risks include rapid progression from cognitive euphoria to confusion and loss of consciousness, delirium during partial consciousness or incomplete reversal, amnesia for the intoxication period, and acute anxiety and dysphoria if antagonists precipitate withdrawal. inferred
Essentially all documented human exposures are unintentional. The compound's potency means the window between onset of subjective effects and unconsciousness is likely seconds to minutes for most routes. inferred
Tolerance & Dependence
No human studies on carfentanil-specific tolerance or dependence exist. All assessments are class-level inferences from µ-opioid receptor pharmacology.
Tolerance develops via receptor desensitization and internalization with repeated agonist exposure. Carfentanil's β-arrestin-biased signaling[21] is associated with enhanced receptor desensitization and potentially faster tolerance development.
Physical dependence follows the typical opioid withdrawal trajectory: Anxiety, Dysphoria, muscle pain, sweating, runny nose, insomnia, and gastrointestinal distress. Given carfentanil's extreme potency and long half-life, withdrawal severity has not been characterized but would be expected to be severe.
Cross-tolerance is expected with all µ-opioid agonists. Dependence liability is high by class inference — sub-nanomolar potency, β-arrestin bias, and extreme euphoric potential combine to suggest rapid and severe dependence formation. The practical barrier to formal characterization is that essentially all human exposures are acute overdose events. inferred
Drug Interactions
No clinical interaction studies exist. All interaction data are from mechanistic reasoning and class-level inference.
CNS depressant synergy is the primary risk. Co-exposure with benzodiazepines, alcohol, other opioids, barbiturates, z-drugs, or gabapentinoids produces synergistic respiratory depression. The majority of carfentanil overdose deaths involve polydrug toxicity,[23] and since carfentanil enters the supply as an adulterant, co-exposure with other depressants is the norm.
Opioid antagonist interactions are altered by carfentanil's unique receptor pharmacology. Naloxone shows 10–100-fold reduced potency against carfentanil-stabilized receptor conformations.[6] Nalmefene demonstrates superior reversal characteristics due to higher receptor affinity and a longer half-life.[28][29] Naltrexone is approximately 65-fold more potent than naloxone at displacing carfentanil from the receptor.[6]
Metabolic interactions are predicted from in vitro data. CYP3A4/3A5 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors, grapefruit juice) are expected to increase carfentanil concentrations and toxicity.[30] safety citation needed
Contraindications
7 knownNo substance-specific contraindication studies exist. The following are class-level inferences.
Absolute contraindications:
- Concurrent CNS depressant use — synergistic respiratory depression is the leading cause of carfentanil-associated death[23]
- Respiratory compromise — any condition reducing breathing reserve (COPD, sleep apnea, pneumonia) lowers the lethal threshold
- Absence of reversal agent access — any exposure context without immediately available naloxone or nalmefene
Relative contraindications:
- CYP3A4/3A5 inhibitor co-administration — expected increase in blood concentrations[30]
- Liver impairment — reduced metabolic clearance may prolong and intensify effects
- Heart conditions — slowed heart rate is a documented effect[24] and may worsen pre-existing cardiac conduction problems
- Pregnancy — opioids cross the placenta and produce neonatal withdrawal; carfentanil's extreme potency amplifies fetal risk inferred
safety citation needed All contraindications are class-level inferences.
Harm Reduction[edit]
Forms & Identification
Carfentanil is never sold as a standalone product to end users. It enters the drug supply as an invisible adulterant in heroin, counterfeit prescription pills, and powder sold as fentanyl. The compound is pharmacologically active at quantities far below the threshold of visual detection — distinguishing a carfentanil-laced sample from an unadulterated one by appearance alone is impossible.
Standard fentanyl test strips do not reliably detect carfentanil,[27] and standard immunoassay drug panels miss it entirely.[13] Only LC-MS/MS provides definitive identification. For people who use unregulated opioids, a negative fentanyl strip result does not rule out carfentanil contamination.
Guidelines
- Never use alone. Carfentanil can cause unconsciousness and respiratory arrest within seconds. A witness who can call for help and administer naloxone is critical.
- Carry naloxone — and carry extra. Standard naloxone doses may be insufficient for carfentanil. Multiple doses should be immediately accessible.
- Start with a test dose. When using any unregulated opioid, use a small amount first and wait. This does not eliminate risk from carfentanil contamination — the compound is active at invisible quantities — but may reduce the probability of a full lethal exposure.
- Avoid mixing with other depressants. Benzodiazepines, alcohol, and other opioids dramatically increase the risk of fatal respiratory depression.
- Use supervised consumption sites where available. Trained staff with naloxone and emergency equipment provide the highest level of protection against overdose death.
Set & Setting
Carfentanil exposure is almost exclusively unintentional. There is no safe set or setting for deliberate use — the margin between an active and lethal dose is effectively zero. For people who use unregulated opioids where carfentanil contamination is possible, the single most important environmental factor is never using alone. A second person who can recognize overdose and administer naloxone is the only practical safeguard against a rapid fatal outcome.
Aftercare & integration. Carfentanil exposure is rarely deliberate, and aftercare is primarily medical. Anyone who survives a carfentanil-related overdose should remain under medical observation for a minimum of several hours — the compound's long half-life and active metabolite create a sustained risk of renarcotization after initial naloxone reversal.
Physical recovery after opioid overdose may involve persistent fatigue, nausea, muscle soreness, and cognitive fog for 24–72 hours. Precipitated withdrawal from naloxone administration can produce intense discomfort including anxiety, agitation, and pain. These symptoms are temporary but distressing, and medical support should be sought if they persist.
Psychological processing is important for survivors and witnesses. Overdose is a traumatic event. Peer support organizations, crisis counseling, and harm reduction services can help with emotional recovery and safety planning to reduce future risk.
Recovery & Support
Opioid dependence — whether involving carfentanil, fentanyl, or heroin — is a treatable condition. Evidence-based options include:
- Opioid agonist therapy (methadone, buprenorphine) — reduces cravings, prevents withdrawal, and lowers overdose risk. This is the most effective treatment for opioid use disorder and can be maintained long-term.
- Naltrexone (extended-release injection) — blocks opioid effects and reduces relapse risk. Requires full detoxification before initiation.
- Peer support — organizations such as SMART Recovery and Narcotics Anonymous provide community-based support.
- Harm reduction services — syringe service programs, naloxone distribution, and supervised consumption sites reduce the immediate risks of ongoing use while supporting pathways to treatment.
Recovery is not linear. Relapse is common and does not represent failure — it represents an ongoing condition requiring adjusted support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
- Slow, shallow, or stopped breathing
- Blue or gray lips and fingertips
- Gurgling or snoring sounds from an unconscious person
- Unresponsive to stimulation (sternal rub, loud voice)
- Chest wall rigidity — the chest feels stiff and does not rise with breaths
Immediate steps
- 1. Call emergency services immediately. Do not wait to see if the person recovers.
- 2. Administer naloxone (intranasal or intramuscular). Give a second dose after 2–3 minutes if there is no response. Carfentanil may require multiple naloxone doses — standard dosing is often insufficient.[6]
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Perform rescue breathing if the person is not breathing and you are trained to do so.
- 5. Stay with the person. Renarcotization is likely — carfentanil's effects outlast naloxone by hours.[17]
What to tell the dispatcher
State that the person is unresponsive with slowed or stopped breathing. Say "possible opioid overdose — may involve carfentanil or fentanyl structural analog." Provide the time symptoms were noticed and any substances known to have been used. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents
Naloxone is the standard opioid antagonist but may require repeated or higher-than-standard doses for carfentanil. Nalmefene, where available, has superior reversal characteristics due to higher receptor affinity and a longer half-life.[28][29] Even after apparent reversal, prolonged medical monitoring is essential — carfentanil's half-life of approximately 5.7 hours far exceeds naloxone's 33-minute half-life.
Legal Status[edit]
Carfentanil is subject to the most stringent international drug control measures. Following a December 2017 WHO recommendation, it was placed in both Schedule I and Schedule IV of the 1961 Single Convention on Narcotic Drugs — the maximum level of international scheduling.[14] In the United States, carfentanil retains Schedule II classification due to its historically accepted veterinary use as Wildnil, even though that use is now effectively discontinued.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I and Schedule IV, 1961 Single Convention | Most stringent international control; WHO recommendation December 2017[14] |
| United States | Schedule II (Controlled Substances Act) | DEA ACSCN 9743; annual manufacturing quota 19 grams (2016); retains Schedule II due to historical veterinary use[10] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment and/or unlimited fine; supply: up to life imprisonment and/or unlimited fine[10] |
| Australia | Schedule 8 (Poisons Standard) | Added June 2017; controlled/restricted substance[10] |
| Canada | Controlled substance | Controlled under federal legislation[10] |
| European Union | Individually scheduled by member states | Formal risk assessment conducted by European drugs agency; widespread scheduling across member states |
| China | Controlled | Regulated March 2017 following identification as major illicit supply source[4] |
Frequently asked questions
What is Carfentanil?
Carfentanil is an ultra-potent synthetic opioid of the anilidopiperidine class, approximately 10,000 times more potent than morphine as an analgesic. It acts as a full µ-opioid receptor agonist developed for veterinary use, with no approved human therapeutic indication.
How long does Carfentanil last?
Total duration by route of administration — Intravenous: 4 – 8 hours; Insufflated: 4 – 10 hours; Transdermal: 4 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Carfentanil?
Psychedex publishes a dosage table for Carfentanil on this page covering these routes of administration: intravenous, insufflated, transdermal. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Carfentanil?
The highest-severity documented interactions for Carfentanil: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Local anesthetics (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Carfentanil addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Carfentanil: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with morphine, fentanyl, heroin, oxycodone, hydromorphone, methadone. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^Swanson DM, Hair LS, Strauch Rivers SR, et al. (2017) Fatalities Involving Carfentanil and Furanyl Fentanyl: Two Case Reports — Journal of analytical toxicology doi:10.1093/jat/bkx037
- [2] ^abcO'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM (2017) Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. — MMWR. Morbidity and mortality weekly report doi:10.15585/mmwr.mm6643e1
- [3]
- [4]
- [5] ^abcdMann J, Samieegohar M, Chaturbedi A, et al. (2022) Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest — Clinical pharmacology and therapeutics doi:10.1002/cpt.2696
- [6] ^abcKahl JH, Gonyea J, Humphrey SM, Hime GW, Boland DM (2018) Quantitative Analysis of Fentanyl and Six Fentanyl Analogs in Postmortem Specimens by UHPLC-MS-MS — Journal of analytical toxicology doi:10.1093/jat/bky054
references
- [1] ^Swanson DM, Hair LS, Strauch Rivers SR, et al. (2017) Fatalities Involving Carfentanil and Furanyl Fentanyl: Two Case Reports — Journal of analytical toxicology doi:10.1093/jat/bkx037
- [2] ^abcO'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM (2017) Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. — MMWR. Morbidity and mortality weekly report doi:10.15585/mmwr.mm6643e1
- [3] ^abcdHsu FL, Walz AJ, Myslinski JM, Kong L, Feasel MG, Goralski TDP, Rose T, Cooper NJ, Roughley N, Timperley CM (2019) Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil — ACS medicinal chemistry letters doi:10.1021/acsmedchemlett.9b00404
- [4]
- [5] ^abcdMann J, Samieegohar M, Chaturbedi A, et al. (2022) Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest — Clinical pharmacology and therapeutics doi:10.1002/cpt.2696
- [6]